Exablate BBBD

DEVICE4 trials

Sponsors

InSightec

Conditions

Brain MetastasesBreast CancerGliomaRecurrent Glioblastoma

Phase 1

Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy

CompletedNCT04417088

InSightecRecurrent Glioblastoma

Start: 2020-11-06End: 2023-12-31Updated: 2026-03-20

Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM

CompletedNCT04440358

InSightecRecurrent Glioblastoma

Start: 2020-10-13End: 2023-12-31Updated: 2026-01-20

Unknown Phase

Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metastases

CompletedNCT03714243

InSightecBrain Metastases, Breast Cancer

Start: 2019-09-18End: 2022-04-28Updated: 2026-03-20

Safety and Effectiveness of Blood-Brain Barrier Disruption (BBBD) in Subjects With Suspected Infiltrating Glioma

WithdrawnNCT04667715

InSightecGlioma

Start: 2024-10-23End: 2024-10-23Updated: 2025-05-02

Related Papers

SURG-98. Clinical outcomes, operational metrics, and translational insights derived from trials of MR-guided, transcranial, microbubble-enhanced focused ultrasound for brain tumors: a 2010-2025 evidence analysis

Neuro-Oncology2025-11-01

MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases.

2021-10-13141 citations